Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.

Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who ...

Dr. Anthony Edge, chair of ISC 2024 and chair of the Permanent Scientific Committee of ISC, discusses some of the key takeaways from this year's meeting and explores the technologies set to transform ...

Dr Arshad Khanani shares insights, including data on anti-VEGF treatment and macular atrophy, fibrosis biomarkers, and PCV combination therapies.

Ameluz-photodynamic therapy in superficial basal cell carcinoma may improve the clearance of target lesions, as shown in ...